Coronavirus - Africa: COVAX expects to start sending millions of COVID-19 vaccines to Africa in February
The roll-out of the AstraZeneca/Oxford AZD1222 vaccine is subject to the vaccine being listed for emergency use by WHO
This planned roll-out is a critical first step to ensuring the continent gets equitable access to vaccines
COVAX has notified countries in Africa of the estimated dose allocation for the first phase of COVID-19 vaccine delivery. The global initiative led by the World Health Organization (WHO), Gavi the Vaccine Alliance and The Coalition for Epidemic Preparedness Innovations (CEPI) aims to start shipping nearly 90 million COVID-19 vaccine doses to the continent in February, in what will be Africa’s largest ever mass vaccination campaign.
The roll-out of the AstraZeneca/Oxford AZD1222 vaccine is subject to the vaccine being listed for emergency use by WHO. The organization is currently reviewing the vaccine and the outcome of the review is expected soon.
“Africa has watched other regions start COVID-19 vaccination campaigns from the side-lines for too long. This planned roll-out is a critical first step to ensuring the continent gets equitable access to vaccines,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “We know no one will be safe until everyone is safe.”
COVAX notified countries through letters which were sent on 30 January 2021. Amid surging demand for COVID-19 vaccines, the final shipments will be based on production capacities of vaccine manufacturers and the readiness of countries. Recipient countries are required to submit finalized national deployment and vaccination plans to receive vaccines from the COVAX facility.
In addition, around 320 000 doses of the Pfizer-BioNTech vaccine have been allocated to four African countries -Cabo Verde, Rwanda, South Africa and Tunisia. This vaccine has received WHO Emergency Use Listing but requires countries to be able to store and distribute doses at minus 70 degrees Celsius. To access an initial limited volume of Pfizer vaccine, countries were invited to submit proposals. Thirteen African countries submitted proposals and were evaluated by a multi-agency committee based on current mortality rates, new cases and trends, and the capacity to handle the ultra-cold chain needs of the vaccine.
“This announcement allows countries to fine-tune their planning for COVID-19 immunization campaigns. We urge African nations to ramp up readiness and finalize their national vaccine deployment plans. Regulatory processes, cold chain systems and distribution plans need to be in place to ensure vaccines are safely expedited from ports of entry to delivery. We can’t afford to waste a single dose,” said Dr Moeti.
The initial phase of 90 million doses will support countries to immunize 3% of the African population most in need of protection, including health workers and other vulnerable groups in the first half of 2021. As production capacity increases and more vaccines become available the aim is to vaccinate at least 20% of Africans by providing up to 600 million doses by the end of 2021.
To complement COVAX efforts, the African Union has secured 670 million vaccine doses for the continent which will be distributed in 2021 and 2022 as countries secure adequate financing. The African Export-Import Bank will facilitate payments by providing advance procurement commitment guarantees of up to US$2 billion to the manufacturers on behalf of countries.
Dr Moeti spoke during a virtual press conference today facilitated by APO Group. She was joined by Hon. Khumbize Kandondo Chiponda, Minister of Health, Malawi and Hon. Dr Daniel Ngamije, Minister of Health, Rwanda. Also on hand to answer questions were Dr Richard Mihigo, Immunization and Vaccine Development Programme Coordinator, WHO Regional Office for Africa, and Dr Nicksy Gumede-Moeletsi, Regional Virologist, WHO Regional Office for Africa.
Distributed by APO Group on behalf of WHO Regional Office for Africa.